ADVFN Logo
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover
Premium Connexion/S'inscrire Profile Icon
CAC 40
7 526,55
(
1,32%
)
Dow Jones
36 247,87
(
0,36%
)
DAX
16 759,22
(
0,78%
)
Brent Oil
75,965
(
0,0%
)
Bitcoin
43 875,71
(
0,36%
)
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) Actualités

ARGX Argen X SE

424,00
-0,50 (-0,12%)
08 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Argen X SE ARGX Euronext Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,50 -0,12% 424,00 17:40:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
424,00 423,30 431,00 424,00 424,50
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202313:40GLOBEargenx Announces European Commission Approval of..
01/11/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202322:30GLOBEargenx announces closing of global offering
20/7/202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202322:01GLOBEargenx announces launch of proposed global offering
17/7/202307:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202315:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21/6/202300:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202307:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202307:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/5/202322:01GLOBEargenx announces results of Annual General Meeting of..
02/5/202307:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/4/202307:00GLOBEargenx to Report First Quarter 2023 Financial Results and..
18/4/202307:00GLOBEargenx Demonstrates Commitment to Redefining Treatment Goals..
17/4/202308:00GLOBEargenx and Genmab Enter Partnership to Advance Antibody..
17/3/202321:01GLOBEargenx Announces Annual General Meeting of Shareholders on..
15/3/202314:25GLOBEargenx Announces UK MHRA Approval of VYVGART for the..
02/3/202307:00GLOBEargenx Reports Full Year 2022 Financial Results and Provides..
27/2/202322:01GLOBEargenx Appoints Steve Krognes to Board of Directors
27/2/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
23/2/202307:00GLOBEargenx to Report Full Year 2022 Financial Results and Fourth..
27/1/202307:00GLOBEargenx Receives Notification of PDUFA Date Extension for SC..
16/1/202319:30GLOBEargenx Announces Extraordinary General Meeting of..
09/1/202307:00GLOBEargenx Highlights 2023 Strategic Priorities Across..
03/1/202307:00GLOBEargenx to Present at 41st Annual J.P. Morgan Healthcare..
12/12/202222:01GLOBEargenx Appoints Ana Cespedes to Board of Directors
10/12/202217:30GLOBEargenx to Present Pivotal ADVANCE Trial Data During ASH..

Dernières Valeurs Consultées

EU
ARGX
Argen X
Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr